Messiah University

Mosaic
Biology Educator Scholarship

Biological Sciences

2011

Malaria Antifolate Resistance With Contrasting Plasmodium
Falciparum Dihydrofolate Reductase (DHFR) Polymorphisms in
Humans and Anopheles Mosquitoes
S. Mharakurwa
T. Kumwenda
M. A. P. Mkulama
M. Musapa
S. Chishimba

See next page for additional authors
Follow this and additional works at: https://mosaic.messiah.edu/bio_ed
Part of the Biology Commons

Permanent URL: https://mosaic.messiah.edu/bio_ed/153
Recommended Citation
Mharakurwa, S.; Kumwenda, T.; Mkulama, M. A. P.; Musapa, M.; Chishimba, S.; Shiff, C. J.; Sullivan, D. J.;
Thuma, Philip; Liu, K.; and Agre, P., "Malaria Antifolate Resistance With Contrasting Plasmodium
Falciparum Dihydrofolate Reductase (DHFR) Polymorphisms in Humans and Anopheles Mosquitoes"
(2011). Biology Educator Scholarship. 153.
https://mosaic.messiah.edu/bio_ed/153

Sharpening Intellect | Deepening Christian Faith | Inspiring Action
Messiah University is a Christian university of the liberal and applied arts and sciences. Our mission is to educate
men and women toward maturity of intellect, character and Christian faith in preparation for lives of service,
leadership and reconciliation in church and society.
www.Messiah.edu

One University Ave. | Mechanicsburg PA 17055

Authors
S. Mharakurwa, T. Kumwenda, M. A. P. Mkulama, M. Musapa, S. Chishimba, C. J. Shiff, D. J. Sullivan, Philip
Thuma, K. Liu, and P. Agre

This article is available at Mosaic: https://mosaic.messiah.edu/bio_ed/153

Malaria antifolate resistance with contrasting
Plasmodium falciparum dihydrofolate reductase (DHFR)
polymorphisms in humans and Anopheles mosquitoes
Sungano Mharakurwaa,b,1, Taida Kumwendaa, Mtawa A. P. Mkulamaa, Mulenga Musapaa, Sandra Chishimbaa,
Clive J. Shiffb, David J. Sullivanb, Philip E. Thumaa,b, Kun Liub, and Peter Agreb,1
a

The Malaria Institute at Macha, Choma, Zambia; and bDepartment of Molecular Microbiology and Immunology, Johns Hopkins Malaria Research Institute,
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205
Contributed by Peter Agre, October 10, 2011 (sent for review May 9, 2011)

Surveillance for drug-resistant parasites in human blood is a major
effort in malaria control. Here we report contrasting antifolate
resistance polymorphisms in Plasmodium falciparum when parasites in human blood were compared with parasites in Anopheles
vector mosquitoes from sleeping huts in rural Zambia. DNA encoding P. falciparum dihydrofolate reductase (EC 1.5.1.3) was ampliﬁed
by PCR with allele-speciﬁc restriction enzyme digestions. Markedly
prevalent pyrimethamine-resistant mutants were evident in human P. falciparum infections—S108N (>90%), with N51I, C59R,
and 108N+51I+59R triple mutants (30–80%). This resistance level
may be from selection pressure due to decades of sulfadoxine/pyrimethamine use in the region. In contrast, cycloguanil-resistant
mutants were detected in very low frequency in parasites from
human blood samples—S108T (13%), with A16V and 108T+16V
double mutants (∼4%). Surprisingly, pyrimethamine-resistant
mutants were of very low prevalence (2–12%) in the midguts of
Anopheles arabiensis vector mosquitoes, but cycloguanil-resistant
mutants were highly prevalent—S108T (90%), with A16V and the
108T+16V double mutant (49–57%). Structural analysis of the dihydrofolate reductase by in silico modeling revealed a key difference
in the enzyme within the NADPH binding pocket, predicting the
S108N enzyme to have reduced stability but the S108T enzyme to
have increased stability. We conclude that P. falciparum can bear
highly host-speciﬁc drug-resistant polymorphisms, most likely reﬂecting different selective pressures found in humans and mosquitoes. Thus, it may be useful to sample both human and mosquito
vector infections to accurately ascertain the epidemiological status
of drug-resistant alleles.

E

mergence of drug-resistant Plasmodium falciparum continues
to pose a key obstacle to malaria control and elimination
efforts (1, 2). It is widely recognized that P. falciparum has a
daunting potential for developing resistance to any drug upon
wider introduction, including the new combination regimens with
or without artemisinin (3–7). Effective public health strategies
for surveillance and containment of resistance are therefore
paramount, and the World Health Organization has urged that
drug efﬁcacy be closely monitored (8).
An instrumental approach widely adopted to help control
programs detect and thwart drug resistance is the molecular
surveillance of drug resistance-conferring P. falciparum mutants.
These molecular markers for resistance are best characterized
for chloroquine (9) and antifolate drugs (10–12). Antifolates are
extensively used across endemic countries in intermittent preventive therapy programs for malaria in pregnant women and in
children (13, 14). Antifolates are also constituents of artemisinin
combination therapy (ACT) regimens, such as proguanil–atovaquone–artesunate and artesunate–sulfadoxine/pyrimethamine.
Antifolate resistance by P. falciparum malaria is well recognized (15). Pyrimethamine resistance was ﬁrst reported in rural
Tanzania >50 y ago (16), suggesting the existence of populations
of mutant organisms in the endemic region rather than rapid
appearance of new mutations. Discovery of pyrimethamineresistant mutations in parasite DNA encoding dihydrofolate
18796–18801 | PNAS | November 15, 2011 | vol. 108 | no. 46

reductase (DHFR) implicated amino acid substitutions at key
residues—S108N, N51I, and C59R, as well as double or triple
mutants (15, 17–19). Cycloguanil, the active metabolite of proguanil, is known to induce a different set of mutations in the gene
encoding parasite DHFR—S108T and A16V, as well as the
double mutant (15, 20, 21). During emergence of resistance, the
mutation at DHFR amino acid codon 108 is known to arise (22),
followed by mutations at the other positions in a stepwise course
accompanied by increasing levels of resistance in the multiple
mutants (11).
A combination of mutations S108N and I164L confers crossresistance to pyrimethamine and cycloguanil, which is heightened when the C59R or N51I is also present. A parallel array
of mutations in the P. falciparum dihydropteroate synthetase
(DHPS) gene at codons 436, 437, 540, and 581 similarly confers
resistance to DHPS inhibitors. Tracking such mutations has
proved valuable for monitoring the emergence of antifolate drug
resistance, as has been a corresponding chloroquine-resistant
marker in the P. falciparum chloroquine-resistant transporter
(Pfcrt) gene (23).
Current monitoring for P. falciparum drug-resistant alleles is
mostly based on genotyping malaria infections in humans found
positive by microscopic analysis of their blood. Infections in
vector mosquitoes are rarely considered, despite the insects being the deﬁnitive host where parasite genetic recombination
occurs. With evident ﬁeld association between mosquito control
and drug-resistant P. falciparum prevalence in humans (24, 25),
we hypothesized that mosquitoes may play a role in inﬂuencing
drug-resistant allele epidemiology. To better deﬁne the existence
of drug-resistant alleles in native populations, we undertook
genomic phenotyping of P. falciparum DNA in parasites from
both humans and vector mosquitoes in an endemic region of
southern Zambia.
Results
Our study of malaria in southern Zambia involved visits to rural
households, where peripheral blood was drawn from the residents by ﬁnger prick and pyrethrum insecticide spray catches
were performed in their sleeping rooms. The region in Choma
District surrounding the settlement of Macha was known to exhibit seasonal malaria with thousands of cases of clinical malaria
seen at the regional hospital. Sulfadoxine/pyrimethamine had
been used in the area for decades. Insecticide-treated bed nets
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DHFR Mutant Parasites in Human Blood. Because pyrimethamine
had been used in the region for decades, resistance polymorphisms were expected in the P. falciparum gene encoding
DHFR. From the 169 blood smear-positive individuals, a random subset of samples from 86 was PCR ampliﬁed. Genotypes
for antifolate-resistant mutations (26) were obtained at one or
more loci from all 86. From the 2,610 blood smear-negative
individuals, a random subset of 475 samples was screened for
submicroscopic parasitemia by the same nested PCR for detection of P. falciparum antifolate-resistant polymorphisms (26).
Only 93 were PCR-positive, and 88 of these were successfully
genotyped for antifolate-resistant mutations at one or more loci,
whereas the other 5 had amplicon products too faint for analysis
of restriction enzyme digestions (26). High levels of pyrimethamine-resistant mutations were observed in each group (Fig. 1
and Table 1). The sentinel mutation, S108N, was practically
saturated (>90%). The other mutants, N51I, C59R, and the
108N+51I+59R triple mutant, were also prevalent (30–80%).
Cycloguanil-resistant mutants were not expected because the
progenitor molecule, proguanil, had not been routinely used in
the region or adopted for the Zambian national malaria control
program, despite clinical trials of the proguanil–atovaquone
regimen (27). The sentinel cycloguanil-resistant mutant S108T
was not detected in samples from blood smear-positive individuals (Fig. 1 and Table 1), but samples from blood smear-negative
individuals revealed S108T, in a modest number (13%). The
second mutant, A16V, and the S108T+A16V double mutants
were not detected in samples from the blood smear-positive
individuals, but they were found in a small percentage of samples
(∼4%) from blood smear-negative individuals.
Because they were predominantly asymptomatic, 145 (83%) of
the 174 individuals whose samples were genotyped were unaware
of having taken antimalarials. Ten (6%) of the others had taken
sulfadoxine/pyrimethamine within the past 2 mo. Proportions of
pyrimethamine-resistant mutants were slightly higher in samples
from these individuals, albeit not statistically signiﬁcant, possibly
due to the limited numbers. None of the individuals whose
samples were typed had previously taken trimethoprim/sulfamethoxazole (Cotrimoxazole or Septrin).
DHFR Mutant Parasites in Vector Mosquitoes. Despite high prevalence of mutant parasites in humans, prevalence of pyrimethamine-resistant mutant parasites was substantially diminished in
midguts of Anopheles vector mosquitoes (Fig. 2 and Table1).
This result was unexpected, because the mosquitoes had acquired parasites from humans as recently as 10 d previously. The
likelihood of ﬁnding these mutants had dropped 100-fold in the
mosquito phase; these differences were highly signiﬁcant statistically (Table 2). Although parasites containing pyrimethamineMharakurwa et al.

A

Human Blood Smear Positive
108
51
59
108+51+59
16
108+16

B

Human Blood Smear Negative
108
51
59
108+51+59
16
108+16
0

10

20

30

40

50

60

70

80

90

100

Prevalence (%)

WT

S108N
N51I
C59R
Pyr-resistant

S108T
A16V
Cyc-resistant

Mixed

Fig. 1. Prevalence of P. falciparum pyrimethamine- and cycloguanil-resistant DHFR mutants in human blood. Finger-prick samples were obtained
from humans with microscopic parasitemia (blood ﬁlm-positive; n = 86; A)
and submicroscopic parasitemia (blood ﬁlm-negative; n = 88; B). DNA was
PCR ampliﬁed and analyzed for allele-speciﬁc polymorphisms by restriction
digestion. y-axis numerals denote DHFR codons. Represented are WT, pyrimethamine-resistant mutants (S108N, N51I, C59R, and triple mutants),
cycloguanil-resistant mutants (S108T, A16V, and double mutant), and mixed
alleles (WT+S108T or S108N+S108T).

resistant mutations were least common in midguts, the sentinel
mutation, S108N, was relatively more prevalent in salivary glands
(>40%) than the other mutations (Fig. 2 and Table 1).
Surprisingly high levels of cycloguanil-resistant mutants were
observed in vector mosquitoes, especially in midgut samples (Fig.
2 and Table 1). Mosquito infections exhibited high prevalence of
cycloguanil-resistant S108T, A16V, and the 108T+16V double
mutant, which are currently believed to be rare or absent in
natural P. falciparum infections of Africa and elsewhere (28).
One midgut infection carried the I164L residue, which, as a
multiple mutant with S108N, C59R, and/or N51I, confers high
levels of resistance to both pyrimethamine and cycloguanil.
Another midgut infection bore a unique I164R residue that has
not been previously described for this locus. The composition of
antifolate-resistant mutants in mosquito infections was independent of feeding status (Table 3).
DNA Sequence Conﬁrmations. Genotypes were conﬁrmed by DNA

sequencing. Amplicons from M3-F/ and F-M4 primers (26) were
analyzed from subsets of human samples (six) and vector mosquito midgut (seven) and salivary gland samples (six). Polymorphisms in the gene encoding P. falciparum DHFR, as
determined by PCR and allele-speciﬁc restriction enzyme
digestions (Figs. 1 and 2 and Table 1), were conﬁrmed by the
DNA sequencing. The sequences ﬂanking the sentinel mutation
site at amino acid codon 108 are shown (Fig. 3).
PNAS | November 15, 2011 | vol. 108 | no. 46 | 18797
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had been introduced 3 y earlier, as had ACT. A severe drought
had occurred the previous year.
After giving informed consent, 2,779 human subjects were
studied. The individuals ranged from 2 wk to 96 y of age, median
age 12 y. Peripheral blood samples from all were examined by
microscopy the same day. Only 169 individuals tested positive for
malaria parasites (referred to as “blood smear-positive”). Most
had low-grade asexual parasitemia, ranging from 38 to 245,000
parasites per microliter (geometric mean parasite density, 1,478;
95% CI, 1,060–2,061 parasites per microliter). Of these, 23
(14%) were pyrexic with axillary temperatures of ≥37.5 °C. Of
the 2,610 individuals that tested negative by microscopy (referred
to as “blood smear-negative”), 65 (2.5%) were pyrexic.
Insecticide spray catches yielded 796 malaria vector mosquitoes from human sleeping rooms. Nearly all (99%) were
Anopheles arabiensis, and the remainder (1%) were Anopheles
funestus. The mosquitoes were examined microscopically and
individually dissected to separate the abdomen from the head and
thorax section. Eighty-one (10%) were positive for P. falciparum
in midguts and 64 (8%) in salivary glands, with only 4 (0.5%)
infected in both body sections.

Table 1. Determinations of P. falciparum DHFR resistant polymorphisms for parasites from
blood smear-positive and -negative humans and from vector mosquito midguts and salivary
glands
Infection
Human blood smear-positive
Mut
S108T
Mut + S108T
WT + mut
WT
Total
Human blood smear-negative
Mut
S108T
Mut + S108T
WT + mut
WT
Total
Mosquito midgut
Mut
S108T
Mut + S108T
WT + mut
WT
Total
Mosquito salivary gland
Mut
S108T
Mut + S108T
WT + mut
WT
Total

S108N

N51I

C59R

S108N+N51I+C59R

A16V

I164L

108T+16V

67
0
0
11
6
84

60
0
0
6
15
81

37
0
0
11
34
82

36
N/A
N/A
N/A
43
79

0
0
0
0
84
84

0
0
0
0
74
74

0
0
0
0
84
84

43
5
2
0
2
52

33
0
0
0
11
44

29
0
0
0
18
47

10
N/A
N/A
N/A
22
32

2
0
0
0
44
46

0
0
0
0
39
39

2
0
0
0
44
46

7
71
2
0
1
81

6
0
0
0
43
49

1
0
0
0
62
63

1
N/A
N/A
N/A
40
41

38
0
0
0
29
67

1*
0
0
1
44
46

33
0
0
0
34
67

27
26
0
1
8
62

7
0
0
0
46
53

11
0
0
0
43
54

4
N/A
N/A
N/A
46
50

2
0
0
0
40
42

0
0
0
0
42
42

1
0
0
0
41
42

Human blood smear-positive, n = 86; human blood smear-negative, n = 88; mosquito midgut, n = 81; mosquito
salivary gland, n = 64. N/A, not applicable.
*Midgut, I164R.

Structural Alterations of DHFR in Resistance Mutants. Atomic
structures of P. falciparum DHFR illustrate the role of Ser-108 in
the function of the wild-type (WT) enzyme and the consequences
of S108N mutation [Protein Data Bank (PDB) ID codes 1J3I
and 3JSU]. Essential for nucleotide biogenesis in all organisms,
DHFR catalyzes reduction of dihydrofolate to tetrahydrofolate
with oxidation of NADPH to NADP+.
Modeling with the WT structure as the template revealed
major structural differences in the mutant enzymes. The binding
pocket for NADPH within the WT DHFR contains an important
2.56-Å hydrogen bond linking the side chain of Ser-108 to the
pyrophosphate moiety of NADPH (Fig. 4A Left). In contrast, the
sentinel pyrimethamine-resistant mutant S108N projects a side
chain that cannot form an effective hydrogen bond, because at
5.40 Å, the distance is too great (Fig. 4A Center). Similar to the
WT enzyme, the cycloguanil mutant S108T maintains the 2.56-Å
hydrogen bond with NADPH (Fig. 4A Right). The extra methyl
group in S108T does not cause any steric collisions but forms
van der Waals interactions with a nearby hydrophobic domain
composed of Met-104, Ile-112, and Ile-164 (Fig. 4B Right).

Discussion
Our studies revealed contrasting drug-resistant polymorphisms
in the P. falciparum gene encoding DHFR. The parasites in
human blood demonstrated high levels of pyrimethamine-resistant mutants, whereas parasites in Anopheles vector mosquitoes exhibited high levels of cycloguanil-resistant mutants. This
surprising contrast raises several questions. Are we using optimal
allele detection methods? What is the role of antifolate drug
resistance in the mosquito phase of malaria? What is the functional signiﬁcance of the structural alterations of parasite DHFR?
18798 | www.pnas.org/cgi/doi/10.1073/pnas.1116162108

Are contrasting drug-resistant polymorphisms unique to a single
malaria-endemic region, or is this a general phenomenon?
Our studies indicate that genotyping human blood smear-positive samples alone may underestimate the true proﬁle of drugresistant alleles. Furthermore, although cycloguanil-resistant
mutants are currently believed to be rare or absent in natural P.
falciparum infections in Africa (28–30), they were found to exist at
high prevalence in the vector population. These mutants, S108T,
A16V, and the double mutant S108T+A16V, are prevalent in
parasites in mosquitoes, even though they are undetected by
current surveillance based on typing human blood smear-positive
samples. Rarer alleles, including I164L, and a unique allele,
I164R, were also observed in vector mosquitoes. Mosquito midgut
infections with P. falciparum were acquired from the human
population within the previous 10 d, indicating that cycloguanilresistant alleles were present in human parasitemia. Detection of
low levels of S108T and A16V in samples from humans with blood
smear-negative infections conﬁrmed this hypothesis. It is likely
that minority alleles in blood smear-positive infections escaped
detection due to selective ampliﬁcation of the dominant alleles
during PCR. In Malawi, for example, presence of the rare I164L
mutant was recently documented in human P. falciparum infections by using a heteroduplex tracking assay (30), but the allele was
then subsequently detected in Kenya at low levels by regular PCR
(31). Inclusion of human submicroscopic parasitemia and vector
infections in epidemiological sampling may therefore facilitate
effective tracking and curtailment of resistant alleles before they
become public health problems. Although the possibility of de
novo origins for mutants cannot be ruled out (32), this expanded
sampling approach would remain useful.
Mharakurwa et al.

Table 3. Odds of P. falciparum DHFR resistant polymorphisms in
mosquitoes with a blood meal compared with unfed mosquitoes

Mosquito Midgut
108
51
59
108+51+59
16

Odds ratio (95% CI)

S108N
S108T
N51I
C59R
A16V
I164L*

0.985
0.971
1.461
2.824
0.833

(0.371–2.616)
(0.379–2.491)
(0.295–7.227)
(0.343–23.255)
(0.274–2.535)
—

P
0.975
0.952
0.924
0.539
0.748
—

Mosquitoes with a blood meal, n = 105; unfed mosquitoes, n = 60.
*Statistics could not be computed because only one sample bore mutant.
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Fig. 2. Prevalence of P. falciparum pyrimethamine- and cycloguanil-resistant DHFR mutants in 796 malaria vector mosquitoes. Spray catches were
obtained. Midguts (A) and salivary gland (B) specimens were separated, and
DNA was PCR ampliﬁed and analyzed for allele-speciﬁc polymorphisms by
restriction digestion conﬁrming midgut infections (n = 81) and mosquito
gland infections (n = 62). y-axis numerals denote DHFR codons. Represented
are WT, pyrimethamine-resistant mutants (S108N, N51I, C59R, and triple
mutants), cycloguanil-resistant mutants (S108T, A16V, and double mutant),
and mixed alleles (WT+S108T or designated mutant+S108T).

Our results point to a pivotal role of mosquitoes in the epidemiology of drug-resistant P. falciparum. Apart from harboring
minority alleles subpatent in humans, An. arabiensis clearly exerted a dramatic depletion (as much as 100-fold) on P. falciparum
pyrimethamine-resistant alleles, despite prevailing sulfadoxine/
pyrimethamine drug pressure in the area. This mosquito selection
phenomenon on P. falciparum polymorphisms is distinct from

Kublin’s in vivo ﬁtness burden in humans (33) and was evidently
independent and opposing to existing drug selection.
We speculate that vector-selective constraints on parasite-resistant polymorphisms may reﬂect ﬁeld links between mosquito
control and suppression of P. falciparum drug resistance, as
reported with sulfadoxine/pyrimethamine and with chloroquine
(24, 25, 34). Increasing prevalence of P. falciparum DHFR WT
alleles was observed in Tanzania after the use of insecticidetreated nets (24). In Zimbabwe, the introduction of indoor residual insecticide spraying (IRS) was associated with a fourfold
reduction in the odds of chloroquine therapeutic failure (25),
despite years of ongoing drug pressure. Cessation of the IRS was
subsequently linked to a rebound in chloroquine resistance (25).
Given the vector-selective pressure on parasite-resistant alleles
observed in this study, it would be expected that mosquito control
may affect the prevalence of drug resistance, and this link should
be considered in control programs.
It is important to understand speciﬁc mechanisms by which the
relative proportions of resistant alleles change between human
and mosquito phases. One possibility might be the disparity in
differentiation to gametocytes reported to occur between WT
and resistant alleles (35). This difference may also relate to the
curious switch in the proportions of S108T and S108N alleles
seen between midgut and salivary gland infections. Drug-resistant alleles are known to be associated with altered biological
ﬁtness of the parasite (36, 37). It is therefore possible that survival differences under immune clearance within the human and
mosquito phases, and presence or absence of drug selection, may
play signiﬁcant roles. Analogous differences were observed in
isolation frequencies of Borrelia species from ticks and human
patients from the same endemic region (38).
The P. falciparum polymorphisms found in humans were
expected from selection pressure due to decades of sulfadoxine/
pyrimethamine use. The underlying basis for P. falciparum polymorphisms in mosquitoes is not clear. Structural modeling
revealed distinct differences between the pyrimethamine-resistant
mutation, S108N, and the cycloguanil-resistant mutation S108T,

Table 2. Odds for key P. falciparum DHFR resistant polymorphisms in human blood smear-positive samples compared with blood
smear-negative samples and mosquito midguts and salivary glands
Odds ratio (95% CI), human microscopy positives compared with
Allele
S108N
N51I
C59R
S108N+N51I+C59R triple mutant
S108T
A16V
S108T+A16V double mutant
I164L

Mosquito midgut

Mosquito salivary gland

101 (34.3–299.0); P < 0.001
32 (11.4–87.6); P < 0.001
88 (11.6–662.5); P < 0.001
18 (1.9–172.2); P < 0.001
—; P < 0.001
—; P < 0.001
—; P = 0.948
—; P = 0.081

15 (5.7–39.5); P < 0.001
29 (10.9–76.5); P < 0.001
6 (2.5–12.2); P < 0.001
5 (1.2–22.7); P < 0.001
—; P < 0.001
—; P = 0.208
—; P < 0.001
—

Human submicroscopic infections
1
1
1
2

(0.4–3.5); P = 0.753
(0.5–4.3); P = 0.684
(0.4–1.8); P = 0.724
(0.6–5.8); P = 0.292
—; P = 0.006
—; P = 0.054
—; P = 0.054
—

Mosquito midgut, n = 165; mosquito salivary gland, n = 146; human submicroscopic infections, n = 147. —, Odds ratio could not be calculated due to zero
frequency in human infections.
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GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA
---------+---------+---------+---------+----310
320
330
340
---------+---------+---------+---------+----GTTGTAGTTATGGGAAGAACAAGCTGGGAAAGCATTCCAAAAAAA
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA
GTTGTAGTTATGGGAAGAACAAACTGGGAAAGCATTCCAAAAAAA
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Fig. 3. DNA sequence alignments for P. falciparum DHFR. DNA ﬂanking
nucleotide 323 (amino acid codon 108) obtained from amplicons M3-F/ (M)
and F-M4 (F) from human (H) and Anopheles mosquito (A) samples are
plotted against standard clone 3D7 (GenBank accession no. AL844503; gene
ID 812524). Nucleotide 323 encoding amino acid 108 is accentuated. AGC
encodes WT S108; AAC encodes Pyr-resistant mutant S108N (blue); ACC
encodes Cyc-resistant mutant S108T (yellow). Identical DNA sequences were
obtained from both duplicate amplicons except one mosquito set (F19 A,
M19 A) and one human set (F2 H, M2 H), which contained mixed infections.
All results conﬁrmed the PCR and restriction enzyme typing.

and these changes may provide a molecular explanation for the
host speciﬁcities. Overall, mutations causing pyrimethamine resistance were all nonconservative substitutions—replacement of

A

S108WT

a serine with an asparagine, an asparagine with an isoleucine, or a
cysteine with an arginine. In contrast, mutations causing cycloguanil resistance were very conservative—replacement of a serine
with a threonine or an alanine with a valine.
The Ser-108 residue plays a key role in DHFR catalysis and
protein structure and may explain the contrasting antifolate-resistant polymorphisms reported here. Previous kinetic studies
(39, 40) showed that S108N is a loss-of-function mutant, consistent with reduced ﬁtness in the mosquito vector despite pyrimethamine-induced selection in humans (Figs. 1 and 2). In
contrast, S108T is a gain-of-function mutant. The speciﬁc activity
of S108T is approximately twice that of the WT, whereas Km
values of this mutant for 7,8-dihydrofolate and NADPH are
<25% of the WT (39). These data suggest that the S108T mutation enhances the DHFR activity, possibly conferring an advantage to the parasite, whereas within the midgut, P. falciparum
parasites carrying this mutation may outgrow WT parasites while
forming oocysts. After rupture of the oocysts, the emerging
sporozoites are nonproliferating. Additionally, because sulfadoxine/pyrimethamine has long been used in this region of
Africa, the advantage of S108T parasites may only apply to the
mosquito cycle, and not the human cycle, because pyrimethamine
imposes selective pressure favoring mutations such as S108N. In
this study, S108T accounts for 90% of alleles in mosquito midgut
infections, supporting the above hypothesis. Nevertheless, it does
not explain why S108T prevalence is not elevated in human
infections during absence of sulfadoxine/pyrimethamine selection
pressure. Future studies will be needed to elucidate the candidate factors underpinning these allele patterns.
The human populations and mosquitoes surveyed in this study
were all from one rural area in southern Zambia. Before general
signiﬁcance can be established, it will be essential to undertake
similar surveys in other areas where malaria is endemic. Polymorphisms in P. falciparum genes encoding resistance to other
antimalarial drugs should also be examined. If contrasting drugresistant phenotypes are conﬁrmed in other regions, it may be
useful to examine both human and vector infections during epidemiological surveillance for antimalarial drug-resistant alleles.
Materials and Methods
See SI Materials and Methods for additional details.
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Fig. 4. Key structural variances at
amino acid 108 in WT and resistant
mutants of P. falciparum DHFR. Represented are crystal structures of WT DHFR
(S108WT) and S108N mutant (PDB ID
codes 1J3I and 3JSU). The structure of the
S108T mutant was derived by molecular
modeling. (A) Note a 2.56-Å hydrogen
bond between the pyrophosphate moiety of NADPH and the hydroxyl group of
the S108 WT or S108T residue; no effective hydrogen bond exists in the S108N
mutant due to the 5.40-Å distance. (B)
Note extra methyl group in the S108T
mutant forms van der Waals interactions
with a nearby hydrophobic area composed of Met-104, Ile-112, and Ile-164.
The side chains of S108WT, S108T,
S108N, Met-104, Ile-112, Ile-164, and
NADPH are highlighted with sticks and
spheres; the hydrogen bond is shown as
the dashed line with the distance labeled, and the protein backbone is
shown in a cartoon model.
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Area and Population. The study was conducted during the 2006–2007 peak
malaria transmission season in 15 representative 25-km2 geographical grids near
Macha in the Southern Province of Zambia. Willing individuals of all ages from
the resident BaTonga communities were eligible to participate in the study.

Structural Modeling. The structure of S108T DHFR mutant was modeled with
PyMol (www.pymol.org) by using the WT DHFR crystal structure (PDB ID
code 1J3I) as the template. The quadruple DHFR mutant structure (PDB ID
code 3JSU) was used as the S108N mutant.

Study Design and Sample Collection. The study was a prospective cross-sectional design. P. falciparum malaria infections in sympatric contemporaneous human and mosquito populations were typed for DHFR-resistant alleles.

Data Analysis. Mantel–Haenzel’s χ2 test and multivariate binary logistic
models were used to analyze differences in composition of resistant alleles
among human and mosquito phases. Odds of resistant mutants were determined from the logistic regression models.
Ethics. The study was approved by both the national (University of Zambia)
research ethics committee and the Johns Hopkins institutional review board.

Assays for Antifolate Drug-Resistant Alleles. P. falciparum was genotyped by
nested PCR and allele-speciﬁc restriction enzyme digestion (26) at DHFR
amino acid codons 108, 51, 59, 16, and 164.
A random subset of six samples from human, seven mosquito midgut, and
six mosquito salivary gland infections were subjected to independent sequence conﬁrmation of P. falciparum amplicons at the Johns Hopkins DNA
analysis core facility.
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DNA Extractions. Mosquito samples were subjected to a simpliﬁed Chelex
protocol (41) for P. falciparum DNA extraction. Human blood samples
spotted on ﬁlter paper were air-dried, and the Chelex protocol (12) was used
to extract parasite DNA

